Norgine enters exclusive licensing agreement with Vir Biotechnology
December 18, 2025Manufacturing and Production Hepatology, Norgine, Vir Biotechnology
Norgine has announced its exclusive licensing agreement with Vir Biotechnology, under which Norgine will commercialise the combination of tobevibart and …
Incyclix appoints Kimberly Blackwell to Board of Directors
December 17, 2025Incyclix, board of directors
Incyclix Bio, a cell cycle control company, has announced the appointment of Kimberly Blackwell to its Board of Directors as …
Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International
December 17, 2025General Manager Europe and International, Hansa Biopharma, vice president
Hansa Biopharma, a commercial-stage biopharmaceutical company focusing on rare immunological conditions, has announced the appointment of Max Sakkajja as Vice …
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
December 16, 2025Regulatory Affairs, Research and Development Asthma & COPD, GSK
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) …
Gilead’s HIV treatment meets primary trial endpoint
December 16, 2025Research and Development Gilead, HIV/AIDS
Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a combination of bictegravir and lenacapavir …
EIFO and FSG invest in Fida Biosystems to accelerate growth
December 15, 2025Sales and Marketing EIFO, FSG, Fida Biosystems
The Export and Investment Fund of Denmark (EIFO) and Fåhraeus Startup and Growth Fund (FSG) have invested 5m euros in …
BioPhorum announces acquisition of Inspired Pharma
December 15, 2025Mergers and Acquisitions BioPhorum, Inspired Pharma
BioPhorum, a global pharmaceutical collaboration group, has announced the acquisition of Inspired Pharma, a provider of specialist pharmaceutical training. The …
Evotec and Bayer announce new kidney disease study
December 11, 2025Research and Development Bayer, Evotec, Nephrology
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney disease, stemming from their previous …
Actithera appoints Darshan Dalal as Chief Medical Officer
December 11, 2025Actithera, chief medical officer
Actithera has announced the appointment of Dr Darshan Dalal as its new Chief Medical Officer. Dalal brings over 15 years …
Pace appoints Ken Beyer as CEO
December 10, 2025CEO, Pace Analytical
Pace, a science and technology company specialising in environmental and life sciences laboratories, has announced the appointment of Ken Beyer …
EpilepsyGTx raises $33m for focal refractory epilepsy gene therapy
December 10, 2025Research and Development EpilepsyGTx, Neurology, epilepsy
EpilepsyGTx, a biotechnology company researching and developing gene therapies for the treatment of refractory epilepsy, has announced $33m raised in …
Breast Cancer Now study to explore personalised drug doses
December 9, 2025Research and Development Breast Cancer Now, Oncology
Breast Cancer Now has announced a new study to evaluate whether personalised drug doses could improve quality of life for …
insitro appoints Stephen Hitchcock and Vijay Pande as scientific advisors
December 9, 2025insitro, scientific advisor
insitro, an AI therapeutics company, has announced the appointment of Stephen Hitchcock and Vijay Pande as scientific advisors. Hitchcock brings …
STADA appoints Ole Wendler Pedersen as Executive VP Legal and General Counsel
December 8, 2025Executive VP Legal and General Counsel, Stada
German pharmaceutical company STADA has announced the appointment of Ole Wendler Pedersen as its new Executive Vice President Legal and …
UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
December 8, 2025Research and Development Neurology, UCB, epilepsy
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can significantly reduce the frequency of …
Teva announces positive results from trial of AJOVY for migraine
December 5, 2025Research and Development Neurology, Teva, migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its treatment for chronic (CM) and …
Vetter announces leadership transition as Thomas Otto retires
December 5, 2025Managing Director, Vetter
Vetter has announced the retirement of managing director Thomas Otto amid strategic plans for restructuring its management team. Otto has …
Samsung Bioepis announces launch of two new denosumab biosimilars in Europe
December 4, 2025Sales and Marketing Oncology, Osteoporosis, Samsung Bioepis
Samsung Bioepis has announced the European launch of Obodence and Xbryk, two new denosumab biosimilars approved for the treatment of …
Medicus Pharma appoints Carolyn Bonner as CFO
December 4, 2025Medicus Pharma, chief financial officer
Medicus Pharma has announced the appointment of Carolyn Bonner as Chief Financial Officer (CFO) in addition to her role as …
Sandoz launches two new bone disease biosimilars in Europe
December 3, 2025Sales and Marketing Oncology, Osteoporosis, Sandoz
Sandoz has announced the European launch of two new bone disease biosimilars. Wyost (denosumab 120 mg) is approved for the …
Latest content
FibroFind appoints Lee Borthwick as CEO
